The effect of bebtelovimab on clinical outcomes in patients with COVID-19: A meta-analysis - 06/06/23
Doi : 10.1016/j.jinf.2023.04.010
Changying Liu 1
Department of Geriatrics, People’s Liberation Army, The General Hospital of Western Theater Command, Chengdu, China
∗Correspondence to: No.18 Wanxiang North Road, High-tech District, Chengdu 610095, Sichuan, China.No.18 Wanxiang North Road, High-tech DistrictChengduSichuan610095China
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Highlights |
• | First meta-analysis on bebtelovimab's impact on COVID-19 outcomes. |
• | Analysis includes 7 articles with 12,889 COVID-19 patients. |
• | Bebtelovimab reduces mortality; no change in hospitalization. |
© 2023
The British Infection Association. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 87 - N° 1
P. 68-71 - juillet 2023 Retour au numéro
Article précédent
- Management of nontuberculous mycobacteria-pulmonary disease: Results from the first UK survey of clinical practice
- Akanksha Mimi Malhotra, Sarah Bryant, Heinke Kunst, Charles S. Haworth, Marc Lipman, on behalf of NTM Network UK
- Characterization of a newly emerging HCV subtype 6xk among Burmese travelers arriving at Ruili Port in Yunnan, China
- Jin Liu, Jie li, Binghui Wang, Yiting Liu, Li Liu, Yang Liu, Yue Feng, Weihong Qin, Xueshan Xia
Bienvenue sur EM-consulte, la référence des professionnels de santé.